146 related articles for article (PubMed ID: 37408115)
1. Chemotherapy-induced release of ADAM17 bearing EV as a potential resistance mechanism in ovarian cancer.
Hugendieck G; Lettau M; Andreas S; Neumann S; Reinhardt N; Arnold P; Theilig F; Bastian L; Rogmans C; Weimer JP; Flörkemeier I; Wesch D; Arnold N; Maass N; Janssen O; Bauerschlag D; Hedemann N
J Extracell Vesicles; 2023 Jul; 12(7):e12338. PubMed ID: 37408115
[TBL] [Abstract][Full Text] [Related]
2. ADAM17 and EGFR regulate IL-6 receptor and amphiregulin mRNA expression and release in cigarette smoke-exposed primary bronchial epithelial cells from patients with chronic obstructive pulmonary disease (COPD).
Stolarczyk M; Amatngalim GD; Yu X; Veltman M; Hiemstra PS; Scholte BJ
Physiol Rep; 2016 Aug; 4(16):. PubMed ID: 27561911
[TBL] [Abstract][Full Text] [Related]
3. ADAM17 inhibition enhances platinum efficiency in ovarian cancer.
Hedemann N; Rogmans C; Sebens S; Wesch D; Reichert M; Schmidt-Arras D; Oberg HH; Pecks U; van Mackelenbergh M; Weimer J; Arnold N; Maass N; Bauerschlag DO
Oncotarget; 2018 Mar; 9(22):16043-16058. PubMed ID: 29662625
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.
Richards FM; Tape CJ; Jodrell DI; Murphy G
PLoS One; 2012; 7(7):e40597. PubMed ID: 22792380
[TBL] [Abstract][Full Text] [Related]
5. The ADAM17-amphiregulin-EGFR axis in mammary development and cancer.
Sternlicht MD; Sunnarborg SW
J Mammary Gland Biol Neoplasia; 2008 Jun; 13(2):181-94. PubMed ID: 18470483
[TBL] [Abstract][Full Text] [Related]
6. ADAM17 is associated with EMMPRIN and predicts poor prognosis in patients with uterine cervical carcinoma.
Xu Q; Ying M; Chen G; Lin A; Xie Y; Ohara N; Zhou D
Tumour Biol; 2014 Aug; 35(8):7575-86. PubMed ID: 24793016
[TBL] [Abstract][Full Text] [Related]
7. Hormone-induced expression of tumor necrosis factor alpha-converting enzyme/A disintegrin and metalloprotease-17 impacts porcine cumulus cell oocyte complex expansion and meiotic maturation via ligand activation of the epidermal growth factor receptor.
Yamashita Y; Kawashima I; Yanai Y; Nishibori M; Richards JS; Shimada M
Endocrinology; 2007 Dec; 148(12):6164-75. PubMed ID: 17901238
[TBL] [Abstract][Full Text] [Related]
8. A disintegrin and metalloproteinase 17 (ADAM17) and epidermal growth factor receptor (EGFR) signaling drive the epithelial response to Staphylococcus aureus toxic shock syndrome toxin-1 (TSST-1).
Breshears LM; Schlievert PM; Peterson ML
J Biol Chem; 2012 Sep; 287(39):32578-87. PubMed ID: 22833676
[TBL] [Abstract][Full Text] [Related]
9. Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.
Huang Y; Benaich N; Tape C; Kwok HF; Murphy G
Int J Biol Sci; 2014; 10(7):702-14. PubMed ID: 25013379
[TBL] [Abstract][Full Text] [Related]
10. Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx.
Horiuchi K; Le Gall S; Schulte M; Yamaguchi T; Reiss K; Murphy G; Toyama Y; Hartmann D; Saftig P; Blobel CP
Mol Biol Cell; 2007 Jan; 18(1):176-88. PubMed ID: 17079736
[TBL] [Abstract][Full Text] [Related]
11. A transforming Src mutant increases the bioavailability of EGFR ligands via stimulation of the cell-surface metalloproteinase ADAM17.
Maretzky T; Zhou W; Huang XY; Blobel CP
Oncogene; 2011 Feb; 30(5):611-8. PubMed ID: 20871631
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
Tanaka Y; Miyamoto S; Suzuki SO; Oki E; Yagi H; Sonoda K; Yamazaki A; Mizushima H; Maehara Y; Mekada E; Nakano H
Clin Cancer Res; 2005 Jul; 11(13):4783-92. PubMed ID: 16000575
[TBL] [Abstract][Full Text] [Related]
13. Caveolin-1 is required for TGF-β-induced transactivation of the EGF receptor pathway in hepatocytes through the activation of the metalloprotease TACE/ADAM17.
Moreno-Càceres J; Caja L; Mainez J; Mayoral R; Martín-Sanz P; Moreno-Vicente R; Del Pozo MÁ; Dooley S; Egea G; Fabregat I
Cell Death Dis; 2014 Jul; 5(7):e1326. PubMed ID: 25032849
[TBL] [Abstract][Full Text] [Related]
14. Extracellular oxidation in cystic fibrosis airway epithelium causes enhanced EGFR/ADAM17 activity.
Stolarczyk M; Veit G; Schnúr A; Veltman M; Lukacs GL; Scholte BJ
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L555-L568. PubMed ID: 29351448
[TBL] [Abstract][Full Text] [Related]
15. A disintegrin and metalloproteinase 17 (ADAM17) mediates epidermal growth factor receptor transactivation by angiotensin II on hepatic stellate cells.
Oikawa H; Maesawa C; Tatemichi Y; Nishinari Y; Nishiya M; Mizugai H; Ikeda A; Oikawa K; Takikawa Y; Masuda T
Life Sci; 2014 Mar; 97(2):137-44. PubMed ID: 24412389
[TBL] [Abstract][Full Text] [Related]
16. Cell surface annexins regulate ADAM-mediated ectodomain shedding of proamphiregulin.
Nakayama H; Fukuda S; Inoue H; Nishida-Fukuda H; Shirakata Y; Hashimoto K; Higashiyama S
Mol Biol Cell; 2012 May; 23(10):1964-75. PubMed ID: 22438584
[TBL] [Abstract][Full Text] [Related]
17. ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.
Wang XJ; Feng CW; Li M
Mol Cell Biochem; 2013 Aug; 380(1-2):57-66. PubMed ID: 23625205
[TBL] [Abstract][Full Text] [Related]
18. ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.
Zheng X; Jiang F; Katakowski M; Zhang ZG; Lu QE; Chopp M
Cancer Biol Ther; 2009 Jun; 8(11):1045-54. PubMed ID: 19395875
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
Bezler M; Hengstler JG; Ullrich A
Mol Oncol; 2012 Oct; 6(5):516-29. PubMed ID: 22841590
[TBL] [Abstract][Full Text] [Related]
20. Mammary ductal morphogenesis requires paracrine activation of stromal EGFR via ADAM17-dependent shedding of epithelial amphiregulin.
Sternlicht MD; Sunnarborg SW; Kouros-Mehr H; Yu Y; Lee DC; Werb Z
Development; 2005 Sep; 132(17):3923-33. PubMed ID: 16079154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
